Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcobra Ltd.

www.alcobra-pharma.com

Latest From Anadys Pharmaceuticals Inc.

Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble

Since Gilead’s $11 billion buyout of Pharmasset in late 2011, large- and mid-cap biotech share prices have been on the rise. Plus news on recent financing activity by Ophthotech, Effector Therapeutics, Karyopharm Therapeutics and Ironwood Pharmaceuticals.

BioPharmaceutical Business Strategies

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.

BioPharmaceutical United States

eFFECTOR Therapeutics raises $45m in Series A

San Diego-based eFFECTOR Therapeutics has raised $45 million in Series A venture capital to develop small molecules that selectively regulate protein synthesis – otherwise known as translation – and advance a cancer drug candidate into human trials within three years.

Cancer

Flush With Cash And Partnered Up, Regulus Turns To Clinical Execution: An Interview With CEO Kleanthis Xanthopoulos

Regulus notched two partnerships and an IPO in 2012, putting it on firmer financial ground. Now, as it transitions to executing on its partnerships and pushing ahead with its internal programs, its task is to demonstrate the clinical utility of its miRNA compounds.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Alcobra Ltd.
  • Senior Management
  • Tomer Berkovitz, PhD, CFO
    Jonathan Rubin, MD, CMO
    David C Baker, Chief Commercial Officer
  • Contact Info
  • Alcobra Ltd.
    Phone: 72-220 4661
    132 Derech Menachem Begin
    39th Fl.
    Tel Aviv, 6701101
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register